Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperat
about
Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutterEvidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesAsian strategy for stroke prevention in atrial fibrillationFrequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillationContinuous use of low-dose warfarin for gastric endoscopic submucosal dissection: a prospective studyMeasures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic reviewQuality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation.Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients.National Stroke Association guidelines for the management of transient ischemic attacks.Medical therapy for secondary prevention of stroke.Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin.The case for an elderly targeted stroke management.Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke: Phase1/2a Clinical Trial in a Homogeneous Group of Stroke PatientsCardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis.Transesophageal echocardiographic findings are independent and relevant predictors of ischemic stroke in patients with nonvalvular atrial fibrillation.Development and Comparison of Warfarin Dosing Algorithms in Stroke PatientsFrequency of adverse events in patients with poor anticoagulation: a meta-analysisUse of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls.Treatment of coagulopathy in intracranial hemorrhage.Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis.Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation.Quality of Anticoagulation with Warfarin in Korean Patients with Atrial Fibrillation and Prior Stroke: A Multicenter Retrospective Observational Study.Evidence-based study on antithrombotic therapy in patients at risk of a stroke with paroxysmal atrial fibrillation.Management of anticoagulation before and after gastrointestinal endoscopy.Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation.Preadmission therapeutic anticoagulation reduces cerebral infarct volume in patients with nonvalvular atrial fibrillation."East asian paradox": challenge for the current antiplatelet strategy of "one-guideline-fits-all races" in acute coronary syndrome.Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation.Stroke: secondary prevention.Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.Differences in Managing Anticoagulants and Antiplatelets for Gastrointestinal Endoscopy between East and West.A survey of reasons for continuing warfarin therapy in the era of direct oral anticoagulants in Japanese patients with atrial fibrillation: the SELECT study.Efficacy and Safety of Uninterrupted Low-Intensity Warfarin for Radiofrequency Catheter Ablation of Atrial Fibrillation in the Elderly.A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.
P2860
Q24245613-EDC714A6-D4AB-4E38-A62D-C8369C109338Q24632951-0FCE6F7A-AA4E-43D7-B631-32E29AA268F8Q28072723-DA5229DB-66F4-4ABB-8C8A-F94573F63209Q28183704-DBBF7A6E-E092-4DEB-8A6F-95F55259476DQ33643975-EE5C6FAB-8287-4F96-9268-80DEF9437835Q33795571-4CFBD6D7-C28E-409B-8B4A-193F8B12BF0DQ33891646-A9B1AD79-EEC1-4987-971B-51A3B363F7A7Q34026245-12156984-33C8-4894-8608-FE52B54051F7Q34202452-1E85DC80-F4CE-42EA-9C7F-6DDFFF5EFF3AQ34233473-481C4A76-67DE-42A7-9339-EA30130E7F57Q34297266-C5818DAA-EE71-42F3-B4AB-DA4009DE3B6EQ34351204-690F4BE0-6CA5-430C-809C-0EF631EF5899Q34557865-C77FDD21-8B69-4C07-AE79-098279C8B7CEQ35008527-52B250FA-5FA0-454A-8DB0-4C5E657C282EQ35204081-382D687D-9583-4F8F-9709-39740EE7AAAFQ35641960-5871BB45-E181-4049-8F1E-CA1E2311251AQ35826999-8A576FFE-9DD2-4CCF-9CB1-73801712BE0CQ36092131-3015FAEA-1DD2-479B-8BF6-266FE6424776Q36240143-1D04F453-947D-47BB-93B3-511A8E605EE2Q36313075-2783AEC0-5E26-4868-B5B5-8F8BDCA1E385Q36707903-FEEF0D62-F257-4177-9C19-5212BE37E3ACQ36827674-8BFFBB9D-3D41-4E36-9F82-FEC09E04674FQ37107710-F776CB79-90F7-4CA8-8D43-9B4AFFB48335Q37788997-4AF8564E-E1EB-4751-B2E7-B68AE4704DC0Q38224507-99BF1C9F-009B-450B-A568-093C895020ADQ38389058-BCA787B0-681E-493F-9015-C06741C766ECQ38658281-9BC528FB-AD65-4D26-9AD1-681BA7151245Q42962900-86917028-39A6-49A3-8292-5038827452C9Q43142488-DB1DFF5A-A1A0-4C9C-AC11-C24968A9728BQ44321220-82C2B103-E291-48EF-9B0D-98C07D649A7AQ44330545-D99ED9DD-CCA2-475F-A7DB-C1A816DEBAC4Q45260812-A14F2CF2-F7B3-4C17-BEDA-6528C501039AQ45937530-E58623E5-CA2A-4D56-8F32-45DDD847767BQ46592441-1948F144-AB85-40A8-8452-D10F1C2DDFD8Q46722175-03DEE426-5CC8-4709-93D6-9A70AF168BC4Q46979156-654C1049-F837-45F3-BA9A-5165112F2CA1Q47146062-B849B9EA-72AB-43B2-9A6A-5E6D59863594Q48506800-58211B1A-D32D-48DA-9007-F211482A1D9BQ48640243-8D42709B-8EF6-4AD3-A159-B071272ED041Q50501003-2D713B83-DFA3-43E9-AA18-A8E9BA39F155
P2860
Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperat
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Optimal intensity of warfarin ...... Secondary Prevention Cooperat
@en
Optimal intensity of warfarin ...... Secondary Prevention Cooperat
@nl
type
label
Optimal intensity of warfarin ...... Secondary Prevention Cooperat
@en
Optimal intensity of warfarin ...... Secondary Prevention Cooperat
@nl
prefLabel
Optimal intensity of warfarin ...... Secondary Prevention Cooperat
@en
Optimal intensity of warfarin ...... Secondary Prevention Cooperat
@nl
P356
P1433
P1476
Optimal intensity of warfarin ...... Secondary Prevention Cooperat
@en
P2093
T Yamaguchi
P304
P356
10.1161/01.STR.31.4.817
P407
P577
2000-04-01T00:00:00Z